Refine by
Patient Program Management Articles & Analysis
183 news found
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer ...
ByTempus
The iGEM (International Genetically Engineered Machine) Competition is an annual event in synthetic biology. Teams participating in iGEM typically spend several months conducting research, designing their projects, and building their biological systems. These projects can range from addressing real-world problems in areas such as healthcare, environmental sustainability, and manufacturing, to ...
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe. With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare ...
CD Genomics, a global leader in genomic and bioinformatics solutions, is pleased to announce the official launch of its Viral Metagenomic Sequencing service. This state-of-the-art offering represents a major advancement in the field of pathogen research and promises to provide unparalleled insights into viral communities. Viruses, being the most abundant entities on our planet, play a pivotal ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
The program involved using Oxford Nanopore’s revolutionary technology to sequence patients at the bedside, dramatically reducing turnaround times to obtaining actionable insights. ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon ...
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
The Next Generation ACO is then responsible for paying all Part A and Part B costs for in-network participating providers and preferred providers with whom it has contracted. In the program, APA ACO took on the risk for all of Medicare Part A and Part B for contracted and participating providers, meaning that APA ACO worked hand-in-hand with its providers to ...
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. “I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to ...
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who reported having a blood glucose meter that includes an app claimed they use the app regularly. Over half of patients surveyed agreed that they consistently follow their healthcare ...
ByLifeScan
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 am ET Location: ...
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the ...
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with heart failure. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting – which brought together the world’s ...
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s ...
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...